G9018 HCPCS Level II code: Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
CMS terminated G9018: its last date of service was Dec 31, 2019. It stays here for looking up older claims; newer services need a current code.
Official description
G9018Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
Short description: Zanamivir,inhalation pwd 10m
HCPCS · United States
Medicare details
The indicators CMS publishes with G9018 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Physician fee schedule – Price established by carriers (e.g., not otherwise classified, individual determination, carrier discretion)
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Dec 1, 2004
- Terminated after
- Dec 31, 2019
Where G9018 sits
- 1G codesProcedures and professional services
- 2Terminated G9018Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code G9018 still valid?
No. CMS terminated G9018; its last date of service was Dec 31, 2019. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover G9018?
CMS lists G9018’s Medicare coverage as “Carrier judgment” and its pricing as “Physician fee schedule – Price established by carriers (e.g., not otherwise classified, individual determination, carrier discretion)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G9018
All G codesG9011Coordinated care fee, risk adjusted maintenance, level 5G9012Other specified case management service not elsewhere classifiedG9013Esrd demo basic bundle level iG9014Esrd demo expanded bundle including venous access and related servicesG9016Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]G9017Amantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)G9019Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)G9020Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)G9033Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)G9034Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)G9035Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)G9036Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)